^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LYL132
i
Other names: LYL132, LYL-132, LYL 132, NY-ESO-1-targeted TCR therapy incorporating Epi-R, GSK4427296
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Lyell Immunopharma
Drug class:
TCR modulator, NY ESO 1 inhibitor
Related drugs:
4d
ZENYTH-ESO: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=12, Terminated, GlaxoSmithKline | Trial completion date: Dec 2025 --> Jun 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jun 2023; The study was terminated due to a change in GSK's R&D priorities.
Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
|
HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
|
cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132
over1year
ZENYTH-ESO: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=11, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=67 --> 11 | Trial completion date: Feb 2024 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Dec 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
|
HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
|
cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132
over1year
ZENYTH-ESO: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=67, Recruiting, GlaxoSmithKline | N=50 --> 67
Enrollment change • Combination therapy
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
|
HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
|
cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132
2years
ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296]. (ASCO 2022)
Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T-cell therapy expressing an affinity-enhanced T-cell receptor (TCR) to improve recognition of cancer cells expressing NY-ESO-1 and/or LAGE-1a. Analyses will be descriptive. The master protocol is open for recruitment.
Clinical • P2 data • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A) • EWSR1 (EWS RNA Binding Protein 1) • CTAG1B (Cancer/testis antigen 1B) • FUS (FUS RNA Binding Protein) • CTAG2 (Cancer/testis antigen 2) • DDIT3 (DNA-damage-inducible transcript 3)
|
HLA-A*02 • CTAG1B expression
|
letetresgene autoleucel (GSK3377794) • LYL132
2years
ZENYTH-ESO: Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=50, Recruiting, GlaxoSmithKline | N=38 --> 50
Enrollment change • Combination therapy
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
|
HLA-A*02:01 • HLA-A*02 • HLA-A2 positive • CTAG2 expression
|
cyclophosphamide • fludarabine IV • GSK3845097 • GSK3901961 • LYL132
Share via
